

This product is for research use only (not for diagnostic or therapeutic use)

contact: support@agrisera.com

Agrisera AB | Box 57 | SE-91121 Vännäs | Sweden | +46 (0)935 33 000 | www.agrisera.com

Product no AS09 527-DL594

## AGO1 | Argonaute 1, DyLight® 594 conjugated (40 µg)

## **Product information**

Immunogen KLH-conjugated, N-terminal peptide of Arabidopsis thaliana AGO1 004379, At1g48410

**Host** Rabbit

Clonality Polyclonal

**Purity** Immunogen affinity purified serum, in PBS pH 7.4, conjugated to DyLight® 594.

Format Liquid in PBS pH 7,4.

Quantity 40 μg

Storage Store at 4°C for 12-18 months, A preservative may be added for long time storage up to 2 years. Spin briefly the tube

**Additional information** Antibody binds microRNA and tasiRNAs, preference for 21nt miRNAs with 5'U,TCA acetone total protein precipitation

method.

DyLight® 594 has Amax = 593 nm, Emax = 618 nm. DyLight® is a registered trademark of Thermofisher Inc., and its

subsidiaries.

## Application information

**Recommended dilution** To be determined by end user.

Expected | apparent

116,4 | 130 kDa

Confirmed reactivity Arabidopsis thaliana, Nicotiana benthamiana

Predicted reactivity Brassica pekinensis, Capsella rubella, Malus domestica, Pisum sativum, Ricinus communis, Vitis vinifera

Species of your interest not listed? Contact us

Not reactive in Chlamydomonas reinhardtii

**Additional information** 

AGO expression may be tissue specific and using floral tissue is recommended where most of the AGOs are expressed the highest. Use of proteasome inhibitors as MG132 can help to stabilize AGO proteins during extraction procedure. The AGO1 antibody is extremely specific to AGO1 and does not cross-react with other antibodies. The evidence is 1) the peptide to which it was raised is at the very N-terminus of the protein and is not present in other AGOs 2) aAGO1 does not cross react with the AGOs which are overexpressed (AGO2, AGO3, AGO4, AGO5, AGO6, AGO9) using a

western blot.

**Selected references** To be added when available. Antibody released in May 2023.